Pharmaceuticals Archives

NS Healthcare is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

Continue Learn More X

Home » Pharmaceuticals » deals

AbbVie to buy neuroscience drugmaker Cerevel Therapeutics for $8.7bn

By NS Healthcare Staff Writer

07 Dec 23

The proposed acquisition will include Cerevel’s clinical-stage pipeline of assets focused on psychiatric and neurological disorders, which will…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

AbbVie to buy neuroscience drugmaker Cerevel Therapeutics for $8.7bn

Roche to acquire US biotechnology company Carmot for up to $3.1bn

By NS Healthcare Staff Writer

05 Dec 23

Through the acquisition, Roche will get access to Carmot’s portfolio of incretins, including its lead asset CT-388, along…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

AbbVie to acquire cancer therapeutics maker ImmunoGen for $10.1bn

By NS Healthcare Staff Writer

01 Dec 23

Through the acquisition of ImmunoGen for a total equity value of around $10.1bn, AbbVie is enabled to advance…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

Merck to buy Caraway Therapeutics for up to $610m

By NS Healthcare Staff Writer

22 Nov 23

Under the agreement, Merck will acquire all the outstanding shares of Massachusetts-based Caraway with earnout milestones related to…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

Astellas to buy US biopharmaceutical firm Propella for $175m

By NS Healthcare Staff Writer

16 Nov 23

Astellas will obtain Propella’s lead candidate PRL-02 (abiraterone decanoate), a next-generation androgen biosynthesis inhibitor intended for the treatment…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates